A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR ...
Abbisko Therapeutics Co. Ltd. on Wednesday entered into a strategic collaboration with AstraZeneca Plc to jointly develop a ...
PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1 negative metastatic lung adenocarcinoma: A real-world data. Analysis of thromboembolic events in patients with ...
Chinese Medical Journals Publishing House Co., Ltd. Numerous EGFR-TKIs are approved for EGFR-sensitive mutation NSCLC, including gefitinib, erlotinib, icotinib, osimertinib, and 11 others. First-line ...
A new collaborative study reports the discovery and application of a novel therapeutic strategy to selectively target EGFR and other kinases with controlled release in tumor microenvironments to ...
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ICIs combined with chemotherapy with or without antiangiogenic therapy (C/A) versus C/A alone in the ...
The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib (Tagrisso) will respond to therapy. But acquired resistance to the tyrosine kinase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results